Skip to main content
Erschienen in: AIDS and Behavior 5/2020

30.10.2019 | Original Paper

Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial

verfasst von: Sarah T. Roberts, Gonasagrie Nair, Jared M. Baeten, Thesla Palanee-Philips, Katie Schwartz, Krishnaveni Reddy, Samuel Kabwigu, Flavia Matovu Kiweewa, Vaneshree Govender, Zakir Gaffoor, Nishanta Singh, Samantha Siva, Kalendri Naidoo, Elizabeth T. Montgomery, for the MTN-020/ASPIRE Team

Erschienen in: AIDS and Behavior | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Although vaginal microbicides for HIV prevention are designed to be female-initiated, male partner influence has been identified as one of the most significant factors impacting women’s willingness and ability to use them. As a result, research teams have sought to increase male partner involvement by encouraging disclosure of product use to male partners, promoting male partner engagement in the study through attendance at the study clinic, and helping women to garner male partner support for product use. This paper aims to assess the impact of these three elements of male partner involvement on women’s adherence to the dapivirine vaginal ring during MTN-020/ASPIRE, a phase III randomized placebo-controlled clinical trial involving 2629 women in Malawi, South Africa, Uganda, and Zimbabwe. During the study, 64–80% of participants reported disclosure of ring use at each quarterly visit, and 13% reported that their partners had attended the study clinic at some point during the study. At study exit, 66% reported that their partner was supportive, 18% unsupportive, and 17% were unsure. After adjusting for age, site and time in study, women were more likely to have low ring adherence if they had an unsupportive male partner (aRR 1.29, 95% CI 1.03–1.62). Neither disclosure nor clinic attendance directly predicted ring adherence, but disclosure increased the probability of having a supportive partner (aRRR 24.17, 95% CI 16.38–35.66) or an unsupportive partner (aRRR 4.10, 95% CI 2.70–6.24), relative to an unknown level of partner support. Women were also more likely to have a supportive partner if their partner had attended the clinic (aRRR 3.77, 95% CI 1.36–10.42). This study suggests that although the vaginal ring is relatively discreet, lack of support from male partners remains a relevant barrier to use. Though both disclosure and clinic attendance may increase partner support, disclosure may also increase partner opposition. Interventions to reduce male partner opposition are needed to maximize the potential impact of the ring and other PrEP products for HIV prevention.
Literatur
1.
Zurück zum Zitat UNAIDS. UNAIDS Reports on the global AIDS epidemic 2010 2010 [http://www.unaids.org/globalreport/default.htm. UNAIDS. UNAIDS Reports on the global AIDS epidemic 2010 2010 [http://​www.​unaids.​org/​globalreport/​default.​htm.​
2.
Zurück zum Zitat Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRef
3.
Zurück zum Zitat Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRef Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRef
4.
Zurück zum Zitat McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329–37.CrossRef McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329–37.CrossRef
5.
Zurück zum Zitat Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61.CrossRef Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61.CrossRef
6.
Zurück zum Zitat Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016;375(22):2121–32.CrossRef Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016;375(22):2121–32.CrossRef
7.
Zurück zum Zitat Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43.CrossRef Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43.CrossRef
8.
Zurück zum Zitat Nel A, Van Neikerk N, Van Baelen B, Roseberg Z (2018) HIV incidence and adherence in dream: an open-label trial of dapivirine vaginal ring. Conference on retroviruses and opportunistic infections (CROI); March 4-7, 2018; Boston, MA, USA. Nel A, Van Neikerk N, Van Baelen B, Roseberg Z (2018) HIV incidence and adherence in dream: an open-label trial of dapivirine vaginal ring. Conference on retroviruses and opportunistic infections (CROI); March 4-7, 2018; Boston, MA, USA.
9.
Zurück zum Zitat Baeten JM, Palanee-Phillips T, Mgodi N, Mayo A, Nel A, Roseberg Z, et al. (2018) High uptake and reduced HIV-1 incidence in an open-label trial of the dapivirine ring. Conference on retroviruses and opportunistic infections (CROI); March 4-7, 2018; Boston, MA, USA. Baeten JM, Palanee-Phillips T, Mgodi N, Mayo A, Nel A, Roseberg Z, et al. (2018) High uptake and reduced HIV-1 incidence in an open-label trial of the dapivirine ring. Conference on retroviruses and opportunistic infections (CROI); March 4-7, 2018; Boston, MA, USA.
10.
Zurück zum Zitat Nel A, Malherbe M, Mans W, Van Baelen B, Van Niekerk N, Louw C, et al. (2019) Safety, adherence and HIV-1 seroconversion in DREAM—an open-label dapivirine vaginal ring trial. 9th SA AIDS Conference; June 11-14, 2019; Durban, South Africa. Nel A, Malherbe M, Mans W, Van Baelen B, Van Niekerk N, Louw C, et al. (2019) Safety, adherence and HIV-1 seroconversion in DREAM—an open-label dapivirine vaginal ring trial. 9th SA AIDS Conference; June 11-14, 2019; Durban, South Africa.
11.
Zurück zum Zitat Baeten J, Palanee-Phillips T, Mgodi N, Ramjee G, Gati B, Mhlanga F, et al. (2019) High uptake and sustained impact on HIV-1 incidence: final results of an open-label extension trial of the dapivirine ring. 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico. Baeten J, Palanee-Phillips T, Mgodi N, Ramjee G, Gati B, Mhlanga F, et al. (2019) High uptake and sustained impact on HIV-1 incidence: final results of an open-label extension trial of the dapivirine ring. 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico.
12.
Zurück zum Zitat Brown E, Palanee-Philips T, Marzinke M, Hendrix C, Dezutti C, Soto-Torres L, et al. (2016) Residual dapivirine ring levels indicate higher adherence to vaginal ring is associated with HIV-1 protection. 21st International AIDS Conference (AIDS 2016); July 11-22, 2016; Durban, South Africa. Brown E, Palanee-Philips T, Marzinke M, Hendrix C, Dezutti C, Soto-Torres L, et al. (2016) Residual dapivirine ring levels indicate higher adherence to vaginal ring is associated with HIV-1 protection. 21st International AIDS Conference (AIDS 2016); July 11-22, 2016; Durban, South Africa.
13.
Zurück zum Zitat Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014;18(5):849–54.CrossRef Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014;18(5):849–54.CrossRef
14.
Zurück zum Zitat van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRef van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRef
15.
Zurück zum Zitat van der Straten A, Montgomery ET, Musara P, Etima J, Naidoo S, Laborde N, et al. Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS. 2015;29(16):2161–71.CrossRef van der Straten A, Montgomery ET, Musara P, Etima J, Naidoo S, Laborde N, et al. Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS. 2015;29(16):2161–71.CrossRef
16.
Zurück zum Zitat Celum C, Gill K, Morton J, Stein G, Myers L, Thomas K, et al. (2019) Incentives conditioned on tenofovir levels to increase adherence among young women on PrEP in Cape Town. 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico. Celum C, Gill K, Morton J, Stein G, Myers L, Thomas K, et al. (2019) Incentives conditioned on tenofovir levels to increase adherence among young women on PrEP in Cape Town. 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico.
17.
Zurück zum Zitat Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T, et al. (2019) Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Cult Health Sex. 2019;Epub ahead of print:1-16. Chitukuta M, Duby Z, Katz A, Nakyanzi T, Reddy K, Palanee-Phillips T, et al. (2019) Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Cult Health Sex. 2019;Epub ahead of print:1-16.
18.
Zurück zum Zitat Duby Z, Katz AWK, Browne EN, Mutero P, Etima J, Zimba CC, et al. (2019) Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2019. Duby Z, Katz AWK, Browne EN, Mutero P, Etima J, Zimba CC, et al. (2019) Hygiene, blood flow, and vaginal overload: why women removed an HIV prevention vaginal ring during menstruation in Malawi, South Africa, Uganda and Zimbabwe. AIDS Behav. 2019.
19.
Zurück zum Zitat van der Straten A, Browne EN, Shapley-Quinn MK, Brown ER, Reddy K, Scheckter R, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81(3):304–10.CrossRef van der Straten A, Browne EN, Shapley-Quinn MK, Brown ER, Reddy K, Scheckter R, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81(3):304–10.CrossRef
20.
Zurück zum Zitat Montgomery E, Napierala S, Zvivamwe P, Mtetwa S, Hammond N, Chipato T, et al. Male involvement in a diaphragm and microbicide safety study in Zimbabwe. Microbicides. 2006;2006:23–6. Montgomery E, Napierala S, Zvivamwe P, Mtetwa S, Hammond N, Chipato T, et al. Male involvement in a diaphragm and microbicide safety study in Zimbabwe. Microbicides. 2006;2006:23–6.
21.
Zurück zum Zitat Montgomery CM. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care. 2008;20(6):733–40.CrossRef Montgomery CM. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care. 2008;20(6):733–40.CrossRef
22.
Zurück zum Zitat Sahin-Hodoglugil NN, van der Straten A, Cheng H, Montgomery ET, Kacanek D, Mtetwa S, et al. Degrees of disclosure: a study of women’s covert use of the diaphragm in an HIV prevention trial in sub-Saharan Africa. Soc Sci Med. 2009;69(10):1547–55.CrossRef Sahin-Hodoglugil NN, van der Straten A, Cheng H, Montgomery ET, Kacanek D, Mtetwa S, et al. Degrees of disclosure: a study of women’s covert use of the diaphragm in an HIV prevention trial in sub-Saharan Africa. Soc Sci Med. 2009;69(10):1547–55.CrossRef
23.
Zurück zum Zitat Montgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women’s acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2010;15(5):959–69.CrossRef Montgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women’s acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2010;15(5):959–69.CrossRef
24.
Zurück zum Zitat Montgomery E, Stadler J, Hartmann M, Magee C, Magazi B, Mathebula F, et al. (ed) (2013) Male partner roles and influence on women’s use of HIV pre-exposure prophylaxis in Johannesburg. AIDS Impact. Sept 29-Oct 3, 2013; Barcelona, Spain Montgomery E, Stadler J, Hartmann M, Magee C, Magazi B, Mathebula F, et al. (ed) (2013) Male partner roles and influence on women’s use of HIV pre-exposure prophylaxis in Johannesburg. AIDS Impact. Sept 29-Oct 3, 2013; Barcelona, Spain
25.
Zurück zum Zitat Lanham M, Wilcher R, Montgomery ET, Pool R, Schuler S, Lenzi R, et al. Engaging male partners in women’s microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc. 2014;17(3 Suppl 2):19159.PubMedPubMedCentral Lanham M, Wilcher R, Montgomery ET, Pool R, Schuler S, Lenzi R, et al. Engaging male partners in women’s microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc. 2014;17(3 Suppl 2):19159.PubMedPubMedCentral
26.
Zurück zum Zitat Succop SM, MacQueen KM, van Loggerenberg F, Majola N, Karim QA, Karim SS. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care. 2014;26(12):1521–5.CrossRef Succop SM, MacQueen KM, van Loggerenberg F, Majola N, Karim QA, Karim SS. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care. 2014;26(12):1521–5.CrossRef
27.
Zurück zum Zitat Palanee-Phillips T, Roberts ST, Reddy K, Govender V, Naidoo L, Siva S, et al. Impact of partner-related social harms on women’s adherence to the dapivirine vaginal ring during a phase III trial. J Acquir Immune Defic Syndr. 2018;79(5):580–9.CrossRef Palanee-Phillips T, Roberts ST, Reddy K, Govender V, Naidoo L, Siva S, et al. Impact of partner-related social harms on women’s adherence to the dapivirine vaginal ring during a phase III trial. J Acquir Immune Defic Syndr. 2018;79(5):580–9.CrossRef
28.
Zurück zum Zitat Celum C, Mgodi N, Bekker LG, Hosek S, Donnel D, Anderson P, et al. (2019) PrEP use in young African women in HPTN 082: Effect of drug level feedback. 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico. Celum C, Mgodi N, Bekker LG, Hosek S, Donnel D, Anderson P, et al. (2019) PrEP use in young African women in HPTN 082: Effect of drug level feedback. 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico.
29.
Zurück zum Zitat Gafos M, Pool R, Mzimela MA, Ndlovu HB, McCormack S, Elford J, et al. Communication about microbicide use between couples in Kwazulu-natal, South Africa. AIDS Behav. 2015;19(5):832–46.CrossRef Gafos M, Pool R, Mzimela MA, Ndlovu HB, McCormack S, Elford J, et al. Communication about microbicide use between couples in Kwazulu-natal, South Africa. AIDS Behav. 2015;19(5):832–46.CrossRef
30.
Zurück zum Zitat Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–67.CrossRef Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159–67.CrossRef
31.
Zurück zum Zitat Laborde ND, Pleasants E, Reddy K, Atujuna M, Nakyanzi T, Chitukuta M, et al. Impact of the dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: managing ring detection and hot sex. AIDS Behav. 2018;22(2):437–46.CrossRef Laborde ND, Pleasants E, Reddy K, Atujuna M, Nakyanzi T, Chitukuta M, et al. Impact of the dapivirine vaginal ring on sexual experiences and intimate partnerships of women in an HIV prevention clinical trial: managing ring detection and hot sex. AIDS Behav. 2018;22(2):437–46.CrossRef
32.
Zurück zum Zitat Stadler J, Delany-Moretlwe S, Palanee T, Rees H. Hidden harms: women’s narratives of intimate partner violence in a microbicide trial, South Africa. Soc Sci Med. 2014;110:49–55.CrossRef Stadler J, Delany-Moretlwe S, Palanee T, Rees H. Hidden harms: women’s narratives of intimate partner violence in a microbicide trial, South Africa. Soc Sci Med. 2014;110:49–55.CrossRef
33.
Zurück zum Zitat Montgomery ET, Upkong M, White R, van der Straten A (ed) (2009). Involving male partners in trials of female-initiated HIV prevention methods in Africa: a review of strategies and evidence. International Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa2009. Montgomery ET, Upkong M, White R, van der Straten A (ed) (2009). Involving male partners in trials of female-initiated HIV prevention methods in Africa: a review of strategies and evidence. International Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa2009.
34.
Zurück zum Zitat Kojima N, Klausner JD. Strategies to increase human immunodeficiency virus testing among men to reach UNAIDS 90-90-90 targets. Clin Infect Dis. 2018;67(9):1468–9.CrossRef Kojima N, Klausner JD. Strategies to increase human immunodeficiency virus testing among men to reach UNAIDS 90-90-90 targets. Clin Infect Dis. 2018;67(9):1468–9.CrossRef
35.
Zurück zum Zitat Huerga H, Van Cutsem G, Ben Farhat J, Puren A, Bouhenia M, Wiesner L, et al. Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey. BMC Public Health. 2018;18(1):303.CrossRef Huerga H, Van Cutsem G, Ben Farhat J, Puren A, Bouhenia M, Wiesner L, et al. Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: a household-based community cross-sectional survey. BMC Public Health. 2018;18(1):303.CrossRef
36.
Zurück zum Zitat Joint United Nations Programme on HIV/AIDS (UNAIDS). Reaching out to men and boys: addressing a blind spot in the response to HIV. Geneva: UNAIDS; 2017. Joint United Nations Programme on HIV/AIDS (UNAIDS). Reaching out to men and boys: addressing a blind spot in the response to HIV. Geneva: UNAIDS; 2017.
37.
Zurück zum Zitat Montgomery ET, Chidanyika A, Chipato T, van der Straten A. Sharing the trousers: gender roles and relationships in an HIV-prevention trial in Zimbabwe. Cult Health Sex. 2012;14(7):795–810.CrossRef Montgomery ET, Chidanyika A, Chipato T, van der Straten A. Sharing the trousers: gender roles and relationships in an HIV-prevention trial in Zimbabwe. Cult Health Sex. 2012;14(7):795–810.CrossRef
38.
Zurück zum Zitat van der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16(7):1775–86.CrossRef van der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16(7):1775–86.CrossRef
39.
Zurück zum Zitat Montgomery E, van der Straten A, Torjesen K. “Male involvement” in women and children’s HIV prevention: challenges in definition and interpretation. J AIDS. 2011;57(5):e114. Montgomery E, van der Straten A, Torjesen K. “Male involvement” in women and children’s HIV prevention: challenges in definition and interpretation. J AIDS. 2011;57(5):e114.
40.
Zurück zum Zitat MacQueen KM, Dlamini S, Perry B, Okumu E, Sortijas S, Singh C, et al. Social context of adherence in an open-label 1% tenofovir gel trial: gender dynamics and disclosure in KwaZulu-Natal, South Africa. AIDS Behav. 2016;20(11):2682–91.CrossRef MacQueen KM, Dlamini S, Perry B, Okumu E, Sortijas S, Singh C, et al. Social context of adherence in an open-label 1% tenofovir gel trial: gender dynamics and disclosure in KwaZulu-Natal, South Africa. AIDS Behav. 2016;20(11):2682–91.CrossRef
41.
Zurück zum Zitat Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099.CrossRef Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099.CrossRef
42.
Zurück zum Zitat McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef
43.
Zurück zum Zitat Gill K, Dietrich J, Gray G, Pidwell T, Kayamba F, Bennie T, et al. (2017) Pluspills: an open label, safety and feasibility study of oral pre-exposure prophylaxis (PrEP) in 15–19 year old adolescents in two sites in South Africa. 9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France. Gill K, Dietrich J, Gray G, Pidwell T, Kayamba F, Bennie T, et al. (2017) Pluspills: an open label, safety and feasibility study of oral pre-exposure prophylaxis (PrEP) in 15–19 year old adolescents in two sites in South Africa. 9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France.
Metadaten
Titel
Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial
verfasst von
Sarah T. Roberts
Gonasagrie Nair
Jared M. Baeten
Thesla Palanee-Philips
Katie Schwartz
Krishnaveni Reddy
Samuel Kabwigu
Flavia Matovu Kiweewa
Vaneshree Govender
Zakir Gaffoor
Nishanta Singh
Samantha Siva
Kalendri Naidoo
Elizabeth T. Montgomery
for the MTN-020/ASPIRE Team
Publikationsdatum
30.10.2019
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 5/2020
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02707-1

Weitere Artikel der Ausgabe 5/2020

AIDS and Behavior 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.